InvestorsHub Logo
Followers 22
Posts 996
Boards Moderated 0
Alias Born 08/01/2016

Re: None

Tuesday, 11/03/2020 6:55:25 PM

Tuesday, November 03, 2020 6:55:25 PM

Post# of 462058
The enclosed is what the SEC "strongly recommends" in reporting TLD:

Increase visibility. If the data is positive, it can be beneficial to conduct an investor call to discuss the data and answer main questions from analysts and investors. Including a KOL on the call is highly recommended to provide insight into clinical implications of the data, its significance to the current treatment paradigm, clinical demand in the market niche, and to attract more analysts and investors to the call by adding scientific credibility to the discussion.

Consider reporting at conferences. Timing of data readout can be relatively predictable and one can plan to report the full set of data at a medical or scientific conference. One caveat: Keep in mind abstract submission deadlines as well as the conference embargo policy.

Publish peer-reviewed data. Publication in peer-reviewed scientific journals is currently the primary method for sharing clinical trial data with the scientific and medical communities, as well as the public through media coverage of the findings. Especially if published in a top-tier scientific journal, highlighting such presentation in a press release will provide visibility for the company as well as the extra level of validation of study findings.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News